20:44 , Apr 18, 2019 |  BC Extra  |  Clinical News

FDA draft guidance suggests comparing bispecifics to monospecific antibodies

Demonstrated efficacy of a bispecific antibody against monospecific products targeting the different antigens could be a requirement for gaining FDA approval, according to draft guidance released Thursday. The guidance describes non-clinical and clinical recommendations for...
11:51 , Apr 18, 2019 |  BC Innovations  |  Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods. Current image analysis tools work well...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
22:40 , Mar 18, 2019 |  BC Extra  |  Financial News

OrbiMed, Arix lead Imara's $63M B round

Imara will use its $63 million series B round to prepare lead compound IMR-687 for a Phase III program in adults with sickle cell disease, and to position the oral phosphodiesterase-9 (PDE-9) inhibitor for pediatric...
02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
23:55 , Mar 14, 2019 |  BC Week In Review  |  Company News

AbCellera, Gates Foundation partner on infectious disease treatments

Antibody company AbCellera partnered with the Bill & Melinda Gates Foundation to develop vaccines and antibody-based therapies to treat infectious diseases. AbCellera Biologics Inc. (Vancouver, B.C.) will receive $4.8 million in funding for the two-year...
21:06 , Feb 28, 2019 |  BC Innovations  |  Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
18:47 , Feb 15, 2019 |  BC Week In Review  |  Financial News

MacroGenics raises $110M in follow-on

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
18:13 , Feb 13, 2019 |  BC Extra  |  Financial News

MacroGenics raises $110M following breast cancer data

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on. MacroGenics sold 5.5 million shares at $20, pricing at a 5%...
13:52 , Jan 29, 2019 |  BC Innovations  |  Distillery Techniques

Drug platforms; other

TECHNOLOGY: Antibody scaffolds; computational models A method of optimizing antibodies for broad activity against different viral strains could be used to generate antibodies to treat infections by influenza and other multi-strain viruses. The method is...